Overview

Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The investigators propose a randomized, double blind, placebo-controlled, cross-over trial to evaluate the effect of oral and topical (vaginal gel) tenofovir on genital herpes simplex virus (HSV) shedding among herpes simplex virus type-2 (HSV-2) seropositive, human immunodeficiency virus (HIV) seronegative women. The investigators hypothesize that tenofovir will reduce genital HSV shedding compared to placebo.
Phase:
Phase 4
Details
Lead Sponsor:
University of Washington
Collaborators:
CONRAD
Gilead Sciences
Treatments:
Tenofovir